Aspergillosis, the leading fungal cause of mortality in
immunocompromised patients, presents a serious worldwide
challenge--particularly in the face of increasing antifungal
resistance. Bringing together the world's leaders in
the Aspergillus and aspergillosis fields to promote
cross-disciplinary collaboration among clinicians, industry, and
scientific experts, the "Advances Against
Aspergillosis" conference was held January 26-28, 2012
in Istanbul, Turkey.

This first of two Annals volumes contains short reviews
encapsulating recent clinical findings on aspergillosis.
Among the topics included are the application of diagnostic markers
to invasive aspergillosis in children, risk stratification for
invasive aspergillosis in immunocompromised patients, use of
biological agents for the treatment of fungal asthma and allergic
bronchopulmonary aspergillosis, immune regulation in
idiopathic bronchiectasis, and management of chronic pulmonary
aspergillosis.

NOTE: Annals volumes are available for sale as individual
books or as a journal. For information on institutional journal
subscriptions, please visit: href="http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.111/(ISSN)1749-6632">http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.111/(ISSN)1749-6632.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences
directly to place your order (href="http://www.nyas.org/">www.nyas.org). Members of the New
York Academy of Science receive full-text access to Annals online
and discounts on print volumes. Please visit href="http://www.nyas.org/MemberCenter/Join.aspx">http://www.nyas.org/MemberCenter/Join.aspx
for more information on becoming a member.